Noradrenaline transporter dysfunction in neural circulatory disorders: clinical, molecular and therapeutic implications

神经循环障碍中的去甲肾上腺素转运蛋白功能障碍：临床、分子和治疗意义

• 批准号: nhmrc : 472669
• 负责人: A/Pr Elisabeth Lambert
• 金额: $ 34.06万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/noradrenaline-transporter-dysfunction-therapeutic-implications/82504
• 关键词: Noradrenaline; transporter; dysfunction; neural; circulatory

We will investigate the clinical relevance of noradrenaline transporter (NET) dysfunction and its molecular and genetic regulation in (1) essential hypertension, (2) postural tachycardia syndrome where the heart rate increases abnormally when the patient assumes an upright position and (3) syncope where subjects experience recurrent blackouts. In a therapeutic approach, we will explore whether NET inhibition can reduce the number of episodes and alleviate the symptoms associated with syncope.

我们将研究去甲肾上腺素转运蛋白（NET）功能障碍及其分子和基因调控在以下疾病中的临床相关性：(1)原发性高血压；(2)体位性心动过速综合征（当患者保持直立姿势时心率异常增加）；(3)晕厥（受试者反复昏厥）。在治疗方法中，我们将探讨NET抑制是否可以减少发作次数并缓解晕厥相关症状。